New York, USA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- A new report on the global bloodstream infection testing market has been added by Research Dive to its repository. According to the report, the global market is expected to hit $7,722.2 million by 2027, rising at a CAGR of 8.4% from 2019 to 2027. This report in an in-depth study offering meticulous insights into the present situation and future scope of the global industry. The report is drafted by expert market analysts and assures to be a reliable source of data and comprehensive market insights for new market players, investors, prevalent players, stakeholders, shareholders, etc.
Factors Impacting the Market Growth
The key factors enhancing the growth of the global bloodstream infection testing market are the surging cases of sepsis and increasing occurrence of infectious ailments. Moreover, growing investments in the research and development activities related to bloodstream infection testing by market players is projected to open doors to profitable opportunities for the growth of the market throughout the forecast period. However, high costs involved in diagnosis and absence of medical compensation in this type of testing are expected to hamper the market growth.
For More Detail Insights, Download Free Sample Copy of the Report at: https://www.researchdive.com/download-sample/8350
COVID-19 Pandemic Impact on the Market
The outbreak of COVID-19 pandemic in 2020 has had an optimistic impact on the growth of the global bloodstream infection testing market. The pandemic has greatly surged the importance and demand for in-vitro diagnostic testing, which is considered as the ideal standard for analysis of infectious ailments. The demand for diagnostic testing increased stupendously mainly in the North American and European regions during the pandemic, which is significantly boosting the market growth.
The report segments the global bloodstream infection testing market into product, technique, technology, application, end user, and region.
Consumables Sub-Segment to Hold a Dominating Position
The consumables sub-segment of the product segment is anticipated to grow with a CAGR of 8.5% and hold a leading position in the market during the forecast period. This is chiefly owing to the increasing awareness regarding the significance of blood bloodstream infection testing in diagnosis of diseases among people.
Conventional Sub-Segment to Hold a Leading Market Share
The conventional sub-segment of the technique segment is estimated to grow with a CAGR of 8.1% and grab a foremost position in the market during the forecast period. This is chiefly owing to the widespread use of conventional diagnosis methods in laboratories.
Molecular Diagnosis Sub-Segment to Register Highest Growth Rate
The molecular diagnosis sub-segment of the technology segment is anticipated to grow profoundly in the estimated period. The growth of this sub-segment is mainly because molecular technology is quicker, more sensitive, dependable, and enables direct identification of causative pathogens.
Connect with Our Analyst to Contextualize Our Insights for Your Business: https://www.researchdive.com/connect-to-analyst/8350
Bacterial Sub-Segment to Observe Highest Growth
The bacterial sub-segment of the application segment is anticipated to observe significant growth with a CAGR of 8.7% during the forecast period. This is chiefly because of the rising demand for bloodstream infection testing owing to the growing occurrence of sepsis in people worldwide.
Hospital Sub-Segment to Hold Highest Market Share
The hospital sub-segment of the end user segment is estimated to grow with a CAGR of 8.0% and grab a leading position in the market during the forecast period. This is chiefly owing to the growing advancements in medical facilities in emerging nations and rising number of sovereign laboratories across the world.
North American Market to Observe Highest Growth
The report analyzes the global bloodstream infection testing market across several regions such as North America, Europe, Asia Pacific, and LAMEA. Among these, the North American region market is estimated to observe notable growth with a CAGR of 7.9% in the forecast period. The growth of this region market is primarily due to the growing elderly population and presence of huge number of healthcare services in this region.
Key Market Players
The report lists some of the foremost players operating in the global bloodstream infection testing industry including -
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd.
- Becton Dickinson
- bioMérieux SA
- Bruker Corp
- Cepheid
- Luminex Corporation
- Thermo Fisher Scientific
- Accelerate Diagnostics Inc.
- AdvanDX
Inquire and Get Quick Access to Top Companies Development Strategies Summary Report
The report also offers several industry-top tactics and approaches such as top strategic moves & developments, product/service range, business performance, Porter five forces analysis, and SWOT analysis of the foremost players, functioning in the global industry. For instance, in March 2020, Abbott, an American multinational medical devices and health care company, proclaimed that the U.S. Food and Drug Administration (FDA) has given out Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the diagnosis of COVID-19, giving out positive outcomes in almost 5 minutes and negative outcomes in 13 minutes.
Top Trending Reports -
- Intelligent Intravenous Infusion Pumps Market - Growing geriatric population and chronic diseases are the major factors driving the market growth
- Medical Scales Market - A Shift of consumers toward a healthy lifestyle increased obesity, and rising cases of chronic diseases are driving the market growth
- Neuromonitoring Device Market - The global neuromonitoring device market size is predicted to generate $8,824.56 million in the 2021-2028 timeframe, growing at a healthy CAGR of 7.2%.
